Key Highlights

  • Nexalis Therapeutics(ASX:NX1) executed a Settlement Deed with Linlithgow Family Office, terminating the LFO Facility with no repayment obligation
  • The company is now progressing RDTI forward funding following the release of LFO's security interest
  • A Phase 2 protocol for IRX-616a (Panic Disorder) has been drafted, with CRO quotes obtained for a prompt restart
  • Clinical site costs for the IRX-211 Phase 2 (Breakthrough Cancer Pain) trial were renegotiated to lower levels

Nexalis Therapeutics Ltd(ASX:NX1) used the September 2026 quarter to resolve legacy financial disputes and prepare its clinical programs for a restart, though the period was characterised by limited clinical activity following the Withdrawal of its previous funding partner.

The Melbourne-based biotechnology company reported that it had executed a Settlement Deed with Linlithgow Family Office (LFO) on 27 August 2026, bringing the LFO Facility dispute to a close. The settlement removes a material source of uncertainty and leaves the company with no Debt or security in favour of LFO.

What Were the Key Terms of the LFO Settlement?

Under the Settlement Deed, the LFO Facility was terminated by mutual agreement, with no further obligations for either party. No payment was made by either side, and Nexalis retained the $0.8 million previously advanced under the facility. LFO's general security agreement was terminated and its PPSR registrations released. Additionally, 38,449,145 Options previously issued to LFO were cancelled, while Nexalis agreed to issue 15,000,000 replacement options with an exercise price of $0.15 and a five-year expiry.

The release of LFO's security is significant because it clears the path for the company to access RDTI forward funding. Nexalis is working with RSM and prospective forward financing partners to finalise a Letter of Comfort covering R&D activities from 1 January to 30 September 2026.

What Is the Status of Nexalis' Drug Pipeline?

Nexalis has three drug candidates in development. IRX-616a, an inhaled treatment for Panic Disorder, completed its Phase 1 trial in 24 healthy volunteers with no serious adverse events. During the quarter, the company prepared a draft Phase 2 protocol and obtained quotes from clinical sites and CROs, positioning the study for a prompt start once funding is available.

IRX-211, an inhaled treatment for Breakthrough Cancer Pain, is in Phase 2. The company renegotiated reduced costs with Genesis Care and the South West Sydney clinical site, providing a more capital-efficient path forward. The recruitment strategy has shifted to the Genesis Care network and South West Sydney, moving away from the original Vitalis site.

SRX-25, an oral treatment for Treatment-Resistant Depression, remains in the planning phase while the company prioritises its Phase 2-ready assets.

What Board Changes Occurred?

Post quarter-end, Sean Williams stepped down as Non-Executive Chairman effective 2 October 2026. Niv Dagan was appointed as Non-Executive Chairman. The company also reported that a deed of settlement with iNGENū CRO Pty Ltd is in draft form and expected to be finalised soon, which would allow close-out of the IRX-616a Phase 1 study.

Where Does Nexalis Stand Going Forward?

The company enters the December quarter with its LFO dispute resolved, its clinical Assets free of third-party security, and its drug programs costed and planned. Strengthening the cash position through RDTI forward funding is the board's immediate priority.